Skip to main content

Michael Mussallem

Equibles does not estimate personal net worth.

About Michael Mussallem

Earlier roles on record: CEO at Edwards Lifesciences Corp (EW) until May 11, 2023. Edwards Lifesciences Corp reported in an 8-K filed March 26, 2024 that Michael Mussallem retired as Non-Executive Chairman and a director of the Board, effective May 7, 2024. Edwards Lifesciences Corp reported in an 8-K filed December 8, 2022 that Michael Mussallem retired as Chief Executive Officer, effective May 11, 2023. Michael Mussallem has spoken on 3 earnings calls across 1 company, most recently for Edwards Lifesciences Corp on April 26, 2023. The companies whose calls Michael Mussallem spoke on are classified in the Healthcare sector.

“On March 26, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the "Company") announced that Michael A. Mussallem informed the Board of Directors (the "Board") of his decision to retire as Non-Executive Chairman and a director of the Board which will be effective in conjunction with the Company's annual meeting of stockholders on May 7, 2024 (the "2024 Annual Meeting").”
Edwards Lifesciences Corp Form 8-K, filed March 26, 2024 · Read the filing
“On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023 (the “2023 Annual Meeting”).”
Edwards Lifesciences Corp Form 8-K, filed December 8, 2022 · Read the filing

Michael Mussallem on recent calls

“We're pleased with our first quarter performance, which exceeded our expectations and reflected an improvement in the healthcare staffing along with strong execution of our patient-focused innovation strategy.”
Chairman, Edwards Lifesciences Corp Q1 FY2023 Earnings Call ·
“During 2022, our company stayed focused on the long term, making meaningful progress on strategic milestones with the potential of transforming patient care. While the challenging environment negatively impacted sales, we still grew 8%.”
CEO, Edwards Lifesciences Corp Q4 FY2022 Earnings Call ·
“The third quarter strengthened our conviction in our company's patient-focused innovation strategy.”
CEO, Edwards Lifesciences Corp Q3 FY2022 Earnings Call ·

Affiliation history

Company network

Recent activity